Estimated log-reduction of BCR-ABL transcripts after 12 months of first-line therapy by treatment arm.

Whereas an estimated 39% of all patients on imatinib achieved a ≥ 3 log reduction in BCR-ABL/BCR ratio at 12 months (20% had a ≥ 3 to < 4 log reduction, 19% had a ≥ 4 log reduction), only 2% of patients on interferon (IFN) + cytarabine (Ara-C) achieved this molecular response within 12 months (P < .001).